Correlation Between PaxMedica, Common and Unicycive Therapeutics

Can any of the company-specific risk be diversified away by investing in both PaxMedica, Common and Unicycive Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining PaxMedica, Common and Unicycive Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between PaxMedica, Common Stock and Unicycive Therapeutics, you can compare the effects of market volatilities on PaxMedica, Common and Unicycive Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in PaxMedica, Common with a short position of Unicycive Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of PaxMedica, Common and Unicycive Therapeutics.

Diversification Opportunities for PaxMedica, Common and Unicycive Therapeutics

-0.77

Correlation Coefficient

PaxMedica, Common  Unicycive Therapeutics

Pay attention - limited upside

The 3 months correlation between PaxMedica, and Unicycive is -0.77. Overlapping area represents the amount of risk that can be diversified away by holding PaxMedica, Common Stock and Unicycive Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Unicycive Therapeutics and PaxMedica, Common is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on PaxMedica, Common Stock are associated (or correlated) with Unicycive Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Unicycive Therapeutics has no effect on the direction of PaxMedica, Common i.e., PaxMedica, Common and Unicycive Therapeutics go up and down completely randomly.

Pair Corralation between PaxMedica, Common and Unicycive Therapeutics

If you would invest  57.00  in Unicycive Therapeutics on September 8, 2024 and sell it today you would earn a total of  16.00  from holding Unicycive Therapeutics or generate 28.07% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	4.76%
Values	Daily Returns

PaxMedica, Common Stock  vs.  Unicycive Therapeutics

PaxMedica, Common Stock

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days PaxMedica, Common Stock has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound primary indicators, PaxMedica, Common is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders.

Unicycive Therapeutics

Risk-Adjusted Performance

17 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Unicycive Therapeutics are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak fundamental indicators, Unicycive Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with PaxMedica, Common and Unicycive Therapeutics

The main advantage of trading using opposite PaxMedica, Common and Unicycive Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if PaxMedica, Common position performs unexpectedly, Unicycive Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Unicycive Therapeutics will offset losses from the drop in Unicycive Therapeutics' long position.

The idea behind PaxMedica, Common Stock and Unicycive Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.